AptarGroup, Inc. Q1 2004 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2004. AptarGroup, Inc. operates in the packaging components industry, developing and selling consumer product dispensing systems. The company is organized into two reportable segments: Dispensing Systems and SeaquistPerfect. As of April 28, 2004, there were 36,548,455 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q1 2004 | Q1 2003 |
|---|---|---|
| Net Sales | $315.6 million | $265.1 million |
| Operating Income | $31.7 million | $30.3 million |
| Net Income | $21.2 million | $19.2 million |
| Diluted EPS | $0.57 | $0.53 |
| Operating Margin | 10.1% | 11.4% |
| Net Cash from Operations | $35.8 million | $22.3 million |
| Cash and Equivalents | $181.6 million | $105.1 million |
| Total Debt (Short & Long Term) | $221.5 million | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 19% year-over-year. Approximately 11% of this increase was driven by a weaker U.S. dollar (Euro strengthened ~16%). Organic sales growth (excluding currency) was approximately 8%.
- Margin Compression: Operating margin decreased from 11.4% to 10.1%. Cost of sales as a percentage of net sales rose to 67.0% from 65.1% due to rising raw material costs (plastic resin), price competition, and the strengthening Euro impacting import costs.
- Unusual Items:
- Custom Tooling: Sales included an $11 million increase in custom tooling, which carries lower margins. A $7 million portion related to a pharmaceutical project that was subsequently canceled by the customer.
- Facility Closure: The company recorded approximately $1.1 million in losses and shutdown/severance charges related to closing a U.S. mold manufacturing facility.
- Asset Sale: A gain of approximately $1 million was realized on the sale of a production building, partially offsetting cost increases.
- Segment Performance:
- Dispensing Systems: Sales up 20% to $261.5 million; EBIT up 5% to $31.3 million.
- SeaquistPerfect: Sales up 16% to $54.2 million; EBIT up 16% to $5.3 million.
Guidance, Outlook, and Risks
- Q2 2004 Guidance: Management anticipates diluted earnings per share in the range of $0.58 to $0.63, compared to $0.58 in Q2 2003. This excludes potential tax refunds of approximately $1.5 million.
- Market Outlook: Positive momentum is expected to continue. Pharmaceutical, food/beverage, and personal care volumes are expected to increase. Fragrance/cosmetic sales are expected to grow slightly.
- Cost Pressures: Raw material costs, specifically plastic resin, rose dramatically in late Q1 and are expected to continue rising in Q2. Passing these costs to customers may be delayed.
- Liquidity: The company entered a new five-year, $150 million revolving credit facility in February 2004. Net debt to net capital ratio improved to 5% from 7%.
- Risks: Key risks include foreign currency fluctuations (Euro exposure), raw material availability and cost, price competition (particularly from Asian suppliers), and the impact of the canceled pharmaceutical project on future revenue.
Investor Verification Checklist
- Verify the impact of the canceled $7 million pharmaceutical custom tooling project on future revenue streams and customer relationships.
- Monitor the ability to pass through rising plastic resin costs to customers in Q2 and beyond.
- Assess the timeline and total cost of the U.S. mold manufacturing facility closure (additional $150k expected in Q2).
- Review the status of the $1.5 million U.S. tax refund filing and its potential impact on Q2 or Q3 tax provisions.
- Track the repatriation of the $30 million foreign dividend and the associated $4.4 million tax payment expected in Q2 or Q3.